Hepatitis C Virus Infection and Hepatocellular Carcinoma

Clinics in Liver Disease

Volumn 12, Issue 3, 2008, Pages 661-674

  Blonski, Wojciech ^a,b   Reddy, K Rajender ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; INTERFERON; RIBAVIRIN;

ALCOHOL CONSUMPTION; ALCOHOL LIVER CIRRHOSIS; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SURGERY; CARCINOGENESIS; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; FATTY LIVER; GENOTYPE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER FIBROSIS; MIXED INFECTION; MORBIDITY; MORTALITY; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PREVALENCE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL RATE; UNITED STATES; VIRUS TRANSMISSION;

CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; HEPATITIS C; HUMANS; INCIDENCE; LIVER NEOPLASMS; RISK FACTORS; WORLD HEALTH;

EID: 46749149199     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2008.03.007     Document Type: Review

References (64)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. El-Serag H.B., and Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132 (2007) 2557-2576
3. El-Serag H.B., and Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340 (1999) 745-750
4. El-Serag H.B. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127 (2004) S27-S34
5. El-Serag H.B., Davila J.A., Petersen N.J., et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139 (2003) 817-823
6. El-Serag H.B., and Mason A.C. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 160 (2000) 3227-3230
7. Hassan M.M., Frome A., Patt Y.Z., et al. Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. J Clin Gastroenterol 35 (2002) 266-269
8. Davila J.A., Morgan R.O., Shaib Y., et al. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 127 (2004) 1372-1380
9. Kulkarni K., Barcak E., El-Serag H., et al. The impact of immigration on the increasing incidence of hepatocellular carcinoma in the United States. Aliment Pharmacol Ther 20 (2004) 445-450
10. Armstrong G.L., Alter M.J., McQuillan G.M., et al. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 31 (2000) 777-782
11. McGlynn K.A., Tarone R.E., and El-Serag H.B. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev 15 (2006) 1198-1203
12. Alter M.J., Kruszon-Moran D., Nainan O.V., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341 (1999) 556-562
13. El-Serag H.B. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 36 (2002) S74-S83
14. Colombo M., Kuo G., Choo Q.L., et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 2 (1989) 1006-1008
15. Fasani P., Sangiovanni A., De Fazio C., et al. High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors. Hepatology 29 (1999) 1704-1707
16. Stroffolini T., Andreone P., Andriulli A., et al. Gross pathologic types of hepatocellular carcinoma in Italy. Oncology 56 (1999) 189-192
17. Bruix J., Barrera J.M., Calvet X., et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 2 (1989) 1004-1006
18. Deuffic S., Poynard T., Buffat L., et al. Trends in primary liver cancer. Lancet 351 (1998) 214-215
19. Okuda K., Fujimoto I., Hanai A., et al. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 47 (1987) 4967-4972
20. Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology 62 Suppl 1 (2002) 8-17
21. Donato F., Boffetta P., and Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 75 (1998) 347-354
22. Sun C.A., Wu D.M., Lin C.C., et al. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol 157 (2003) 674-682
23. Corrao G., and Arico S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology 27 (1998) 914-919
24. Koike K. Molecular basis of hepatitis C virus-associated hepatocarcinogenesis: lessons from animal model studies. Clin Gastroenterol Hepatol 3 (2005) S132-S135
25. Moriya K., Fujie H., Shintani Y., et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 4 (1998) 1065-1067
26. Moriya K., Nakagawa K., Santa T., et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 61 (2001) 4365-4370
27. Okuda M., Li K., Beard M.R., et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 122 (2002) 366-375
28. Moriya K., Todoroki T., Tsutsumi T., et al. Increase in the concentration of carbon 18 monounsaturated fatty acids in the liver with hepatitis C: analysis in transgenic mice and humans. Biochem Biophys Res Commun 281 (2001) 1207-1212
29. Moriya K., Yotsuyanagi H., Shintani Y., et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 78 Pt 7 (1997) 1527-1531
30. Perlemuter G., Sabile A., Letteron P., et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 16 (2002) 185-194
31. Lerat H., Honda M., Beard M.R., et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 122 (2002) 352-365
32. Tsutsumi T., Suzuki T., Moriya K., et al. Alteration of intrahepatic cytokine expression and AP-1 activation in transgenic mice expressing hepatitis C virus core protein. Virology 304 (2002) 415-424
33. Tsutsumi T., Suzuki T., Shimoike T., et al. Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity. Hepatology 35 (2002) 937-946
34. Tsutsumi T., Suzuki T., Moriya K., et al. Hepatitis C virus core protein activates ERK and p38 MAPK in cooperation with ethanol in transgenic mice. Hepatology 38 (2003) 820-828
35. Moriishi K., Okabayashi T., Nakai K., et al. Proteasome activator PA28gamma-dependent nuclear retention and degradation of hepatitis C virus core protein. J Virol 77 (2003) 10237-10249
36. Miyoshi H., Fujie H., Shintani Y., et al. Hepatitis C virus core protein exerts an inhibitory effect on suppressor of cytokine signaling (SOCS)-1 gene expression. J Hepatol 43 (2005) 757-763
37. Tagger A., Donato F., Ribero M.L., et al. Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Brescia HCC Study. Int J Cancer 81 (1999) 695-699
38. Donato F., Tagger A., Chiesa R., et al. Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy. Brescia HCC Study. Hepatology 26 (1997) 579-584
39. Donato F., Tagger A., Gelatti U., et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 155 (2002) 323-331
40. Hassan M.M., Hwang L.Y., Hatten C.J., et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 36 (2002) 1206-1213
41. Yuan J.M., Govindarajan S., Arakawa K., et al. Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S. Cancer 101 (2004) 1009-1017
42. Chiaramonte M., Stroffolini T., Vian A., et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 85 (1999) 2132-2137
43. Komura T., Mizukoshi E., Kita Y., et al. Impact of diabetes on recurrence of hepatocellular carcinoma after surgical treatment in patients with viral hepatitis. Am J Gastroenterol 102 (2007) 1939-1946
44. Ohata K., Hamasaki K., Toriyama K., et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 97 (2003) 3036-3043
45. Pekow J.R., Bhan A.K., Zheng H., et al. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer 109 (2007) 2490-2496
46. Kumar D., Farrell G.C., Kench J., et al. Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C. J Gastroenterol Hepatol 20 (2005) 1395-1400
47. Bruno S., Silini E., Crosignani A., et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 25 (1997) 754-758
48. Silini E., Bottelli R., Asti M., et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study. Gastroenterology 111 (1996) 199-205
49. Lopez-Labrador F.X., Ampurdanes S., Forns X., et al. Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma. J Hepatol 27 (1997) 959-965
50. Graham C.S., Baden L.R., Yu E., et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 33 (2001) 562-569
51. Garcia-Samaniego J., Rodriguez M., Berenguer J., et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 96 (2001) 179-183
52. Brau N., Fox R.K., Xiao P., et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol 47 (2007) 527-537
53. El-Serag H.B., Hampel H., and Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 4 (2006) 369-380
54. Reid A.E. Nonalcoholic steatohepatitis. Gastroenterology 121 (2001) 710-723
55. Moore M.A., Park C.B., and Tsuda H. Implications of the hyperinsulinaemia-diabetes-cancer link for preventive efforts. Eur J Cancer Prev 7 (1998) 89-107
56. El-Serag H.B., Richardson P.A., and Everhart J.E. The role of diabetes in hepatocellular carcinoma: a case-control study among United States veterans. Am J Gastroenterol 96 (2001) 2462-2467
57. Adinolfi L.E., Gambardella M., Andreana A., et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33 (2001) 1358-1364
58. Tanaka K., Ikematsu H., Hirohata T., et al. Hepatitis C virus infection and risk of hepatocellular carcinoma among Japanese: possible role of type 1b (II) infection. J Natl Cancer Inst 88 (1996) 742-746
59. Murase J., Kubo S., Nishiguchi S., et al. Correlation of clinicopathologic features of resected hepatocellular carcinoma with hepatitis C virus genotype. Jpn J Cancer Res 90 (1999) 1293-1300
60. Zein N.N., Poterucha J.J., Gross Jr. J.B., et al. Increased risk of hepatocellular carcinoma in patients infected with hepatitis C genotype 1b. Am J Gastroenterol 91 (1996) 2560-2562
61. Omata M., Yoshida H., and Shiratori Y. Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy. Clin Gastroenterol Hepatol 3 (2005) S141-S143
62. Papatheodoridis G.V., Papadimitropoulos V.C., and Hadziyannis S.J. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther 15 (2001) 689-698
63. Hung C.H., Lee C.M., Lu S.N., et al. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J Viral Hepat 13 (2006) 409-414
64. Di Bisceglie A.M., Shiffman M.L., Everson G.T., et al. Prolonged antiviral therapy with peginterferon to prevent complications of advanced liver disease associated with hepatitis C: results of the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) trial. Hepatology 46 (2007) 80A